Xlife Sciences AG - Asset Resilience Ratio

Latest as of December 2025: 0.13%

Xlife Sciences AG (XLS) has an Asset Resilience Ratio of 0.13% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Xlife Sciences AG (XLS) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CHF646.47K

≈ $817.31K USD Cash + Short-term Investments

Total Assets

CHF517.12 Million

≈ $653.78 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Xlife Sciences AG's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see XLS asset base.

Liquid Assets Composition Over Time

This chart breaks down Xlife Sciences AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read XLS liabilities breakdown for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF0.00	0%
Short-term Investments	CHF646.47K	0.13%
Total Liquid Assets	CHF646.47K	0.13%

Asset Resilience Insights

Limited Liquidity: Xlife Sciences AG maintains only 0.13% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Xlife Sciences AG Industry Peers by Asset Resilience Ratio

Compare Xlife Sciences AG's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Xlife Sciences AG (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Xlife Sciences AG.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.13%	CHF646.47K ≈ $817.31K	CHF517.12 Million ≈ $653.78 Million	+0.11pp
2024-12-31	0.02%	CHF99.03K ≈ $125.20K	CHF540.37 Million ≈ $683.18 Million	-0.02pp
2023-12-31	0.04%	CHF218.71K ≈ $276.51K	CHF511.99 Million ≈ $647.30 Million	0.00pp
2022-12-31	0.05%	CHF221.04K ≈ $279.45K	CHF490.23 Million ≈ $619.78 Million	-0.36pp
2021-12-31	0.41%	CHF1.96 Million ≈ $2.47 Million	CHF480.06 Million ≈ $606.93 Million	-2.13pp
2020-12-31	2.53%	CHF4.70 Million ≈ $5.95 Million	CHF185.68 Million ≈ $234.75 Million	+0.88pp
2019-12-31	1.65%	CHF2.54 Million ≈ $3.21 Million	CHF154.02 Million ≈ $194.72 Million	--

pp = percentage points

About Xlife Sciences AG

SW:XLS Switzerland Biotechnology

Market Cap

$93.70 Million

CHF74.11 Million CHF

Market Cap Rank

#20177 Global

#194 in Switzerland

Share Price

CHF12.85

Change (1 day)

+2.80%

52-Week Range

CHF12.50 - CHF26.00

All Time High

CHF52.00